Twist Bioscience Corp vs Wix.Com Ltd — how do they compare? Twist Bioscience Corp trades at $160.26 (market cap $10.08B), while Wix.Com Ltd trades at $75.12 (market cap $3.11B). The key difference: Twist Bioscience Corp is far larger — about 3.2× Wix.Com Ltd's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Wix.Com Ltd for 62 Days on average.
| TWST | WIX | |
|---|---|---|
Market Cap | $10.08B | $3.11B |
Volume | 4,229,037 | 809,286 |
Sector | Health | Technology |
52-Week High | $205.00 | $145.54 |
52-Week Low | $25.45 | $40.43 |
Typical Hold Time | 27 Days | 62 Days |
Enterprise Value | $10.01B | $4.19B |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Wix.com (WIX) trades at $72.97, down 1.27% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth reaching $1.99B in 2025, though net income margin remains negative at -8.19%. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing. Multiple class action lawsuits filed in September 2026 create significant legal overhang.
While analyst consensus remains bullish with 63% buy ratings and $77 price target, the combination of negative cash flow trends, legal challenges, and high valuation multiples (P/E 62.84) presents substantial risk. The stock faces headwinds from operational execution challenges despite solid revenue growth fundamentals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →